Effects of Vitamin D Supplementation on Plasma Aldosterone and Renin-A Randomized Placebo-Controlled Trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

The authors sought to evaluate the effect of vitamin D supplementation on plasma aldosterone concentration (PAC) in patients with hypertension and 25-hydroxyvitamin D[25(OH)D] insufficiency.

Why It Was Studied

The Styrian Vitamin D Hypertension Trial was a single-center, double-blind, placebo-controlled randomized clinical trial conducted from 2011 to 2014.

Who Took Part

The study group was 188 participants.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

Two hundred patients with arterial hypertension and 25(OH)D levels <30 ng/mL were enrolled.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

What Was Measured

PubMed files the paper under topics including Aldosterone, Dietary Supplements, Hypertension, Renin, Vitamin D and Vitamin D Deficiency.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 188 participants.

The publication is from 2016 (Journal of clinical hypertension (Greenwich, Conn.)), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.